PD-L1 Inhibitor Articles


  • [Immunotherapy for the treatment of prostate cancer-a comeback?]

    Prostate cancer (PCA) seems to be more of an immunologic desert than other tumor entities. It is striking that only rarely does prostate cancer show abundant immune cells and a proimmunogenic microenvironment.

    Published October 23, 2018
  • Durvalumab in urothelial cancers.

    Urothelial bladder cancer is one of the most predominant malignancies worldwide with a poor prognosis when presented at an advanced or metastatic stage. Improving the therapeutic landscape in this setting has been an unmet medical need.

    Published March 9, 2018
  • Immune checkpoint inhibitors for urothelial carcinoma.

    Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most common histological type of cancer. Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC (mUC) and the preferred treatment option in the perioperative (neoadjuvant and/or adjuvant) setting of muscle invasive bladder cancer (MIBC).

    Published September 14, 2018